Oral agents for the treatment of type 2 diabetes mellitus: Pharmacology, toxicity, and treatment

被引:89
|
作者
Harrigan, RA [1 ]
Nathan, MS [1 ]
Beattie, P [1 ]
机构
[1] Temple Univ Hosp & Med Sch, Div Emergency Med, Philadelphia, PA 19140 USA
关键词
D O I
10.1067/mem.2001.114314
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Currently available oral agents for the treatment of type 2 diabetes mellitus include a variety of compounds from 5 different pharmacologic classes with differing mechanisms of action, adverse effect profiles, and toxicities. The oral antidiabetic drugs can be classified as either hypoglycemic agents (sulfonylureas and benzoic acid derivatives) or antihyperglycemic agents (biguanides, alpha -glucosidase inhibitors, and thiazolidinediones). In this review, a brief discussion of the pharmacology of these agents is followed by an examination of the adverse effects, drug-drug interactions, and toxicities. Finally, treatment of sulfonylurea-induced hypoglycemia is described, including general supportive care and the management of pediatric sulfonylurea ingestions. The adjunctive roles of glucagon, diazoxide, and octreotide for refractory hypoglycemia are also discussed.
引用
收藏
页码:68 / 78
页数:11
相关论文
共 50 条
  • [1] Oral treatment of type 2 diabetes mellitus
    Palitzsch, K. -D.
    [J]. DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2012, 137 (38) : 1859 - 1872
  • [2] The treatment of type 1 diabetes mellitus with agents approved for type 2 diabetes mellitus
    Munir, Kashif M.
    Davis, Stephen N.
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (15) : 2331 - 2341
  • [3] Cost-effectiveness of oral hypoglycaemic agents for the treatment of type 2 diabetes mellitus
    Ward, A
    O'Brien, JA
    Salas, M
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (04) : 601 - 608
  • [4] Overview of clinically approved oral antidiabetic agents for the treatment of type 2 diabetes mellitus
    He, Zhi-Xu
    Zhou, Zhi-Wei
    Yang, Yinxue
    Yang, Tianxin
    Pan, Si-Yuan
    Qiu, Jia-Xuan
    Zhou, Shu-Feng
    [J]. CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2015, 42 (02) : 125 - 138
  • [5] Imeglimin: The first of a new class of oral agents for the treatment of type 2 diabetes mellitus
    Papazafiropoulou, A. K.
    Aloumanis, K.
    Papanas, N.
    [J]. ARCHIVES OF HELLENIC MEDICINE, 2023, 40 (04): : 467 - 471
  • [6] Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus
    Bell, David S. H.
    [J]. ANNALS OF INTERNAL MEDICINE, 2017, 167 (01) : 74 - 75
  • [7] Pharmacology, Efficacy, and Safety of Linagliptin for the Treatment of Type 2 Diabetes Mellitus
    Neumiller, Joshua J.
    [J]. ANNALS OF PHARMACOTHERAPY, 2012, 46 (03) : 358 - 367
  • [8] Natural products for the treatment of type 2 diabetes mellitus: Pharmacology and mechanisms
    Xu, Lina
    Li, Yue
    Dai, Yan
    Peng, Jinyong
    [J]. PHARMACOLOGICAL RESEARCH, 2018, 130 : 451 - 465
  • [9] ORAL-AGENTS IN THE TREATMENT OF DIABETES-MELLITUS TYPE-II
    ALBERT, J
    EKOE, JM
    [J]. SEMAINE DES HOPITAUX, 1983, 59 (29-3): : 2135 - 2140
  • [10] Oral Semaglutide (Rybelsus) for the Treatment of Type 2 Diabetes Mellitus
    Semenya, Afi Mansa
    Wilson, Stephen A.
    [J]. AMERICAN FAMILY PHYSICIAN, 2020, 102 (10) : 627 - 628